These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17939752)

  • 1. Application of PatchXpress planar patch clamp technology to the screening of new drug candidates for cardiac KCNQ1/KCNE1 (I Ks) activity.
    Trepakova ES; Malik MG; Imredy JP; Penniman JR; Dech SJ; Salata JJ
    Assay Drug Dev Technol; 2007 Oct; 5(5):617-27. PubMed ID: 17939752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
    Guo L; Guthrie H
    J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride.
    Zeng H; Penniman JR; Kinose F; Kim D; Trepakova ES; Malik MG; Dech SJ; Balasubramanian B; Salata JJ
    Assay Drug Dev Technol; 2008 Apr; 6(2):235-41. PubMed ID: 18471077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action potential clamp and mefloquine sensitivity of recombinant 'I KS' channels incorporating the V307L KCNQ1 mutation.
    El Harchi A; McPate MJ; Zhang YH; Zhang H; Hancox JC
    J Physiol Pharmacol; 2010 Apr; 61(2):123-31. PubMed ID: 20436212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization.
    Lee HA; Kim EJ; Hyun SA; Park SG; Kim KS
    Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):614-8. PubMed ID: 20406211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels.
    Sun DD; Wang HC; Wang XB; Luo Y; Jin ZX; Li ZC; Li GR; Dong MQ
    Eur J Pharmacol; 2008 Aug; 590(1-3):317-21. PubMed ID: 18573250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic probucol treatment decreases the slow component of the delayed-rectifier potassium current in CHO cells transfected with KCNQ1 and KCNE1: a novel mechanism of QT prolongation.
    Taniguchi T; Uesugi M; Arai T; Yoshinaga T; Miyamoto N; Sawada K
    J Cardiovasc Pharmacol; 2012 Apr; 59(4):377-86. PubMed ID: 22189896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of Ca(v)1.2 screening with an automated planar patch clamp platform.
    Balasubramanian B; Imredy JP; Kim D; Penniman J; Lagrutta A; Salata JJ
    J Pharmacol Toxicol Methods; 2009; 59(2):62-72. PubMed ID: 19367686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation.
    Liu H; Yang L; Jin MW; Sun HY; Huang Y; Li GR
    Pharmacol Res; 2010 Nov; 62(5):384-90. PubMed ID: 20674746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing use-dependent inhibition of the cardiac Na(+/-) current (I(Na)) in the PatchXpress automated patch clamp.
    Penniman JR; Kim DC; Salata JJ; Imredy JP
    J Pharmacol Toxicol Methods; 2010; 62(2):107-18. PubMed ID: 20601018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp.
    Dubin AE; Nasser N; Rohrbacher J; Hermans AN; Marrannes R; Grantham C; Van Rossem K; Cik M; Chaplan SR; Gallacher D; Xu J; Guia A; Byrne NG; Mathes C
    J Biomol Screen; 2005 Mar; 10(2):168-81. PubMed ID: 15799960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of recombinant human cardiac KCNQ1/KCNE1 channels (I (Ks)) stably expressed in HEK 293 cells.
    Dong MQ; Lau CP; Gao Z; Tseng GN; Li GR
    J Membr Biol; 2006 Apr; 210(3):183-92. PubMed ID: 16909339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autonomic control of cardiac action potentials: role of potassium channel kinetics in response to sympathetic stimulation.
    Terrenoire C; Clancy CE; Cormier JW; Sampson KJ; Kass RS
    Circ Res; 2005 Mar; 96(5):e25-34. PubMed ID: 15731462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
    Vigneault P; Kaddar N; Bourgault S; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):690-5. PubMed ID: 21394035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.
    Haraguchi Y; Ohtsuki A; Oka T; Shimizu T
    BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L; Wible BA; Wan X; Ficker E
    J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
    Qu Y; Gao B; Fang M; Vargas HM
    J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel.
    Sanguinetti MC; Curran ME; Zou A; Shen J; Spector PS; Atkinson DL; Keating MT
    Nature; 1996 Nov; 384(6604):80-3. PubMed ID: 8900283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds.
    Tao H; Santa Ana D; Guia A; Huang M; Ligutti J; Walker G; Sithiphong K; Chan F; Guoliang T; Zozulya Z; Saya S; Phimmachack R; Sie C; Yuan J; Wu L; Xu J; Ghetti A
    Assay Drug Dev Technol; 2004 Oct; 2(5):497-506. PubMed ID: 15671647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.